Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
Roche to start new Elevidys study following setback in Europe [Yahoo! Finance]
Sarepta Therapeutics (SRPT) had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a "sector perform" rating on the stock.
Sarepta Therapeutics (SRPT) had its price target raised by Wedbush from $29.00 to $35.00. They now have an "outperform" rating on the stock.
Sarepta Therapeutics (SRPT) had its price target raised by Deutsche Bank Aktiengesellschaft from $12.00 to $14.00. They now have a "sell" rating on the stock.